About Finacea

Develop a rosacea routine.
Find something that works and stick to it! Preventing flares is the key to long-term success

What is FINACEA? FINACEA is unique — it is the first and only FDA-approved gel for treating the bumps, pimples and associated redness of mild to moderate rosacea.

When you have mild to moderate rosacea, an effective topical treatment can help. To learn more, read about the benefits of FINACEA below and talk to your dermatologist about which treatment is best for you.

By using FINACEA you can take
control of managing your mild to
moderate rosacea.

FINACEA starts working quickly...

Patients in two clinical studies who used FINACEA saw their symptoms improve in as early as 4 weeks.

...and keeps working:

In one clinical trial, FINACEA patients continued to experience improvement through the entire 15 weeks of the study. The patient group using another topical treatment in this study did not show continued improvement after 8 weeks.*

The active ingredient in
FINACEA is naturally- occurring:

FINACEA contains AzA (azelaic acid), a naturally-occurring ingredient that comes in a water-based gel. FINACEA is free of fragrance or alcohol which helps to limit allergic reaction and dryness.

FINACEA may help improve your skin's appearance:

AzA, the active ingredient in FINACEA, has anti-inflammatory, antioxidant and antimicrobial properties. AzA may help reduce skin thickness and even skin tone.

FINACEA is easy to use:

You can incorporate FINACEA into your skin care routine and use it with non-irritating skin care products and cosmetics. Simply apply it before you moisturize, and then follow with your normal makeup routine.

Before and After

Check out the results of patients with mild to moderate Rosacea

Go now

* Results are for individual patients. Not all patients have the same results.

INDICATION & USAGE

FINACEA is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

IMPORTANT SAFETY INFORMATION

FINACEA is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. FINACEA is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety - Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with a dark complexion, these patients should be monitored for early signs of hypopigmentation.

Other than FINACEA, Intendis, Inc. (part of the Bayer group) does not promote or endorse any products or recommendations made by third parties. All products and brand names listed are the property and responsibility of their respective trademark and copyright holders.

Intendis, Inc. reserves the right to terminate or modify this program at its sole discretion and without notice.

Home Prescribing information Terms of Use Privacy Policy About Intendis Contact us